WO2006001029A2 - Compositions antiretrovirales - Google Patents

Compositions antiretrovirales Download PDF

Info

Publication number
WO2006001029A2
WO2006001029A2 PCT/IN2004/000184 IN2004000184W WO2006001029A2 WO 2006001029 A2 WO2006001029 A2 WO 2006001029A2 IN 2004000184 W IN2004000184 W IN 2004000184W WO 2006001029 A2 WO2006001029 A2 WO 2006001029A2
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
starch
lamivudine
sodium
tablet
Prior art date
Application number
PCT/IN2004/000184
Other languages
English (en)
Other versions
WO2006001029A3 (fr
Inventor
Pothireddy Venkateswar Reddy
Muppidi Vanaja
Original Assignee
Hetero Drugs Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hetero Drugs Limited filed Critical Hetero Drugs Limited
Priority to PCT/IN2004/000184 priority Critical patent/WO2006001029A2/fr
Publication of WO2006001029A2 publication Critical patent/WO2006001029A2/fr
Publication of WO2006001029A3 publication Critical patent/WO2006001029A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine

Definitions

  • the present invention relates to stable pharmaceutical compositions of antiretrovirals.
  • Zidovudine chemically, 3'-Azido-3'-deoxythymidine; azidothymidine; or AZT is a reverse transcriptase inhibitor.
  • the therapeutic uses of zidovudine and related compounds, and their preparations were disclosed in U.S. Patent No. 4,724,232.
  • Zidovudine is commercially available as 100 mg capsule, 300 mg tablet, 10 mg/mL in 20-mL single-use vial and 50 mg/5 mL in 240 mL syrup. It is sold under the name RETROVIR.
  • Lamivudine chemically, (2R-cis)-4-Amino-1-[2-(hydroxymethyl)-1 ,3- oxathiolan-5-yl]-2(/H)-pyrimidinone; (-)-2'-deoxy-3'-thiacytidine; (-)-1-[(2f?,5S)-2- (hydroxymethyl)-i ,3-oxathiolan-5-yl]cystosine; or 3TC is a reverse transcriptase inhibitor.
  • the therapeutic uses of lamivudine and related compounds and their preparations were disclosed in WO 91/17159.
  • Lamivudine is commercially available as 100 mg, 150 mg and 300 mg tablets; 10 mg/mL in 240 mL oral solution. It is sold under the name EPIVIR. The combination of lamivudine and zidovudine is commercially available as 150 mg and 300 mg tablets. It is sold under the name COMBIVIR. Stavudine, chemically, 2', 3'-Didehydro-3'-deoxythymidine; 1-(2,3- dideoxy- ⁇ -g/ycero-pent-2-enofuranosyl)thymine; or 3'-deoxy-2'-thymidinene is a reverse transcriptase inhibitor.
  • Stavudine is commercially available as 15 mg, 20 mg, 30 mg and 40 mg capsules; and 1 mg/mL in 200 ml oral solution. It is sold under the name ZERIT.
  • Nevirapine chemically, 11-Cyclopropyl-5,11-dihydro-4-methyl-6/-/- dipyrido[3,2-b: 2', 3'-e][1 ,4]diazepin-6-one is a non-nucleoside reverse transcriptase inhibitor (NNRTI).
  • NRTI non-nucleoside reverse transcriptase inhibitor
  • Nevirapine is commercially available as 200 mg tablet and 50 mg/5 mL in 240 mL oral suspension. It is sold under the name VIRAMUNE.
  • U.S. Patent No. 6,113,920 disclosed a pharmaceutical composition comprising two active pharmaceutical ingredients namely lamivudine and zidovudine and a pharmaceutically acceptable glidant ingredient in the form of a film coated tablet.
  • the PCT application WO 00/18383 disclosed antiviral combination of (S)-2-ethyl-7-fluoro-3-oxo-3,4-dihydro-2H-quinoxaline-1 -carboxylic acid isopropyl ester and zidovudine and/or lamivudine.
  • the present invention provides stable pharmaceutical formulations for combination products of i) zidovudine, lamivudine and nevirapine; ii) lamivudine and stavudine; and iii) nevirapine, lamivudine and stavudine tablets.
  • the pharmaceutical composition may be for example, in the form of a tablet, a caplet, a pellet, a capsule, a granule, a pil, a powder or a sachet.
  • the pharmaceutical composition is in the form of a tablet.
  • the capsule may contain a powder, a compressed powder or a granule.
  • the pharmaceutical composition of the present invention is administered orally.
  • each tablet In developing new tablet dosage formulations, it is necessary to balance the often-competing needs of marketing and production areas. In order to properly do so, each tablet much is uniform in weight and contains the appropriate amount of active ingredient, good flowability of formulations.
  • the tablet formulations must be physically and chemically stable. Proper choice of method of manufacture and selection of excipients is critical.
  • the active component of each tablet must be readily available as needed; hence the tablets must have the proper type of drug release and the appropriate dissolution characteristics.
  • the tablets must have the mechanical integrity to withstand damage during manufacturing, packaging and use. The chosen method of manufacture must be efficient, reproducible, and amenable to automation.
  • the tablets must be elegant in appearance.
  • the present invention provides a formulation suitable for forming tablet io comprising in parts by weight from about 25% to about 35% zidovudine, from about 15% to about 25% nevirapine, from about 10% to about 20% lamivudine, from about 10% to about 30% microcrystalline cellulose, from about 2.5% to about 10% starch, from about 1.0% to about 2.5% croscarmellose sodium, from about 1.0% to about 2.0% polyvinylpyrrolidone K-30, from about 1.0% to about 15 2.0% magnesium stearate, from about 0.5% to about 1.5% colloidal anhydrous silica, from about 1.5% to about 3% crospovidone, from about 1.75% to about 2.5% opadry white.
  • additional excipient/s may be used.
  • the additional excipients include pharmaceutical lubricants, disintegrators, binders, glidents, fillers or mixtures thereof.
  • the preferable tablet formulation is zidovudine (300 mg), nevirapine (200 mg) and lamivudine (150 mg), which comprises in parts by weight from about 28% to about 33% zidovudine, from about 14% to about 17% lamivudine, from about 18% to about 22% nevirapine, from about 17% to about 20% microcrystalline cellulose, from about 6% to about 7.5% starch, from about 1.5% 25 to about 2% croscarmellose sodium, from about 1.5% to about 2.0% polyvinylpyrrolidone K-30, from about 1.25% to about 1.75% magnesium stearate, from about 0.75% to about 1 % colloidal anhydrous silica, from about 11.5% to about 2% crospovidone and about 2% opadry white.
  • Lamivudine and stavudine formulation • 30
  • the present invention provides a formulation suitable for forming tablet comprising in parts by weight from about 25% to about 35% lamivudine, from about 4% to about 10% stavudine, from about 10% to about 25% microcrystalline cellulose, from about 20% to about 35% lactose, from about 5% to about 15% starch, from about 0.5% to about 2.5% croscarmellose sodium, from about 0.1% to about 0.6% lake sunset yellow or lake quinoline yellow, from about 0.5% to about 5% polyvinylpyrrolidone k-30, from about 1 % to about 3% magnesium stearate, from about 0.25% to about 2% colloidal anhydrous silica and from about 1.0% to about 3% sodium starch glycollate.
  • additional excipient/s may be used.
  • the additional excipients include pharmaceutical lubricants, disintegrators, binders, glidents, fillers or mixtures thereof.
  • the preferable tablet formulations are: i) Lamivudine (150 mg) and stavudine(30 mg) tablets; which comprises in parts by weight from about 28% to about 32% lamivudine, from about 5.5% to about 6.5% stavudine, from about 14% to about 18% microcrystalline cellulose, from about 26% to about 31% lactose, from about 9% to about 11 % starch, from about 1.5% to about 2% croscarmellose sodium, from about 0.3% to about 0.5% lake sun set yellow, from about 1.5% to about 2.5% polyvinylpyrrolidone K-30, from about 1.5% to about 2.5% magnesium stearate, from about 0.5% to about 1% colloidal anhydrous silica and from about 2.25 to about 3% sodium starch glycollate; ii) Lami
  • Nevirapine, lamivudine and stavudine formulation The present invention provides a formulation suitable for forming tablet comprising in parts by weight from about 20% to 35% nevirapine, from about 15% to about 25% lamivudine, from about 2% to about 8% stavudine, from about 23% to about 35% lactose, from about 5% to about 10% starch, from about 0.5% to about 4% croscarmellose sodium, from about 0.1% to about 0.4% lake sunset yellow or lake quinoline yellow, from about 1% to about 3.5% polyvinylpyrrolidone k-30, from about 1.0% to about 2.5% magnesium stearate, from about 0.5% to about 1.5% colloidal anhydrous silica and from about 1.0% to about 4.0% sodium starch glycollate.
  • additional excipient/s may be used.
  • the additional excipients include pharmaceutical lubricants, disintegrators, binders, glidents, fillers or mixtures thereof.
  • the preferable tablet formulations are: i) Nevirapine(200mg), lamivudine(150mg) and stavudine(30mg) tablets; which comprises in parts by weight from about 26% to about 31% nevirapine, from about 19% to about 23% lamivudine, from about 4% to about 4.5% stavudine, from about 25% to about 30% lactose, from about 7% to about 8.5 % starch, from about 2% to about 2.5% croscarmellose sodium, from about 0.25% to 0.35% lake sun set yellow, from about 2% to about 3% polyvinylpyrrolidone K-30, from about 1.5% to about 2% magnesium stearate, from about 0.5% to 1.25% colloidal anhydrous silica and from about 2.5% to about 3%
  • the filler includes, but is not limited to calcium carbonate, dibasic calcium phosphate, lactose, magnesium carbonate, magnesium oxide, lactose anhydrous, microcrystalline cellulose, mannitol or mixtures thereof.
  • the lubricant includes, but is not limited to stearic acid, a salt of stearic acid, talc, sodium stearyl fumarate, glyceryl behenate, magnesium silicate, magnesium trisilicate, hydrogenated castor oil or mixtures thereof.
  • the disintegrator includes, but is not limited to sodium starch glycolate, starch, croscarmellose sodium, crospovidone, carboxymethyl cellulose calcium, carboxymethylcellulose sodium, magnesium aluminium silicate or mixtures thereof.
  • the glidents may be for example colloidal anhydrous silica, talc or mixtures thereof.
  • the binder includes, hydroxypropyl cellulose, polyvinylpyrrolidone k-30, hydroxypropyl cellulose(low-substituted), starch or mixtures thereof.
  • Other ingredients such as diluents, stabilizers and antiadherants, conventionally used for pharmaceutical formulations may be included in the present formulation.
  • Example 1 The components and their amounts was as follows:
  • the above formulation was prepared as follows. Granulation of active ingredients including zidovudine(300mg), lamivudine(150mg), nevirapine(200mg) with additives like microcrystalline cellulose(184mg), starch(66mg) and croscarmellose sodium(9mg) was done in a planetary mixer and mixed for 5 to 20 minutes. Binder solution (polyvinylpyrrolidone K-30 (16mg) in purified water) is added to contents of planetary mixer and mixed to get dough mass. The dough mass was dried, and dried granules passed through #16.
  • Binder solution polyvinylpyrrolidone K-30 (16mg) in purified water
  • LAMIVUDINE AND STAVUDINE COMBINATION TABLETS A pharmaceutical composition was prepared according to the method of examples 2 and 3. An active ingredients lamivudine , stavudine and a mixture of microcrystalline cellulose, lactose, starch, croscarmellose sodium, polyvinylpyrrolidone K-30, lake quinoline yellow, lake sunset yellow, sodium starch glycollate, magnesium stearate and colloidal anhydrous silica.
  • Example 2 The components and their amounts was as follows: Lamivudine (150mg) and stavudine(30mg) tablets:
  • the above formulation was prepared as follows. Granulation of active ingredients including lamivudine(150mg), stavudine(30mg) with additives like microcrystalline cellulose( ⁇ mg), lactose(143.5mg), starch(50mg), croscarmellose sodium(3.5mg) and lake sunset yellow(2mg) was done in a planetary mixer and mixed for 5 to 20 minutes. Binder solution (polyvinylpyrrolidone K-30 (10mg) in purified water) is added to contents of planetary mixer and mixed to get dough mass. The dough mass was dried, and dried granules passed through #18.
  • active ingredients including lamivudine(150mg), stavudine(30mg) with additives like microcrystalline cellulose( ⁇ mg), lactose(143.5mg), starch(50mg), croscarmellose sodium(3.5mg) and lake sunset yellow(2mg) was done in a planetary mixer and mixed for 5 to 20 minutes
  • Example 3 The components and their amounts was as follows: Lamivudine (150mg) and stavudine(40mg) tablets.
  • the above formulation was prepared as follows. Granulation of active ingredients including lamivudine(150mg), stavudine(40mg) with additives like microcrystalline cellulose(75mg), lactose(138.5mg), starch(50mg), croscarmellose sodium(3.5mg) and lake quinolline yeilow(2mg) was done in a planetary mixer and mixed for 5 to 20 minutes. Binder solution (polyvinylpyrrolidone K-30(10mg) in purified water) is added to contents of planetary mixer and mixed to get dough mass. The dough mass was dried, and dried granules passed through #18.
  • active ingredients including lamivudine(150mg), stavudine(40mg) with additives like microcrystalline cellulose(75mg), lactose(138.5mg), starch(50mg), croscarmellose sodium(3.5mg) and lake quinolline yeilow(2mg)
  • Example 4 An active ingredients nevirapine, lamivudine, stavudine and a mixture of lactose, starch, croscarmellose sodium, polyvinylpyrrolidone K-30, lake quinoline yellow, lake sunset yellow, magnesium stearate, sodium starch glycollate and colloidal anhydrous silica.
  • Example 4 The components and their amounts were as follows: Nevirapine (200mg), lamivudine (150mg) and stavudine(30mg) tablets.
  • the above formulation was prepared as follows. Granulation of active ingredients including nevirapine(200mg), lamivudine(150mg), stavudine(30mg) with additives like lactose(193.1mg), starch(55.4mg), croscarmellose sodium(9mg) and lake sunset yellow(2mg) was done in a planetary mixer and mixed for 5 to 20 minutes. Binder solution (polyvinylpyrrolidone K-30 (17mg) in purified water) is added to contents of planetary mixer and mixed to get dough mass. The dough mass was dried, and dried granules passed through #18.
  • active ingredients including nevirapine(200mg), lamivudine(150mg), stavudine(30mg) with additives like lactose(193.1mg), starch(55.4mg), croscarmellose sodium(9mg) and lake sunset yellow(2mg) was done in a planetary mixer and mixed for
  • Example 5 The components and their amounts was as follows: Nevirapine (200mg), lamivudine (150mg) and stavudine(40mg) tablets.
  • the above formulation was prepared as follows. Granulation of active ingredients including nevirapine(200mg), lamivudine(150mg), stavudine(40mg) with additives like lactose(183.1mg), starch(55.4mg), croscarmellose sodium(9mg) and lake q.uinolline yel!ow(2mg) was done in a planetary mixer and mixed for 5 to 20 minutes. Binder solution (polyvinylpyrrolidone K-30(17mg) in purified water) is added to contents of planetary mixer and mixed to get dough mass. The dough mass was dried, and dried granules passed through #18.
  • active ingredients including nevirapine(200mg), lamivudine(150mg), stavudine(40mg) with additives like lactose(183.1mg), starch(55.4mg), croscarmellose sodium(9mg) and lake q.uin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des préparations pharmaceutiques stables pour des produits composites comprenant i) des comprimés de zidovudine, de lamivudine et de nevirapine; ii) de lamivudine et de stavudine; et iii) de nevirapine, de lamivudine et de stavudine. Par exemple, le procédé décrit dans cette invention permet d'obtenir une préparation de comprimés stable comprenant de la zidovudine, de la lamivudine, de la nevirapine, de la cellulose microcristalline, de l'amidon, du sodium de croscarmellose, du polyvinylpyrrolidone K-30, du stéarate de magnésium, de la silice anhydre colloïdale, du crospovidone et de l'opadry blanc.
PCT/IN2004/000184 2004-06-25 2004-06-25 Compositions antiretrovirales WO2006001029A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IN2004/000184 WO2006001029A2 (fr) 2004-06-25 2004-06-25 Compositions antiretrovirales

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2004/000184 WO2006001029A2 (fr) 2004-06-25 2004-06-25 Compositions antiretrovirales

Publications (2)

Publication Number Publication Date
WO2006001029A2 true WO2006001029A2 (fr) 2006-01-05
WO2006001029A3 WO2006001029A3 (fr) 2006-05-11

Family

ID=35782186

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2004/000184 WO2006001029A2 (fr) 2004-06-25 2004-06-25 Compositions antiretrovirales

Country Status (1)

Country Link
WO (1) WO2006001029A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006086865A2 (fr) * 2005-02-21 2006-08-24 Fundacão Oswaldo Cruz-Fiocruz Composition pharmaceutique, processus de preparation de cette composition, utilisation de cette composition dans le traitement de l'immunodeficience causee par une infection par le vih et technique de traitement associee
EP2207553A1 (fr) * 2007-10-02 2010-07-21 Emory University Combinaisons puissantes de zidovudine et médicaments qui réalisent une sélection de la mutation k65r dans la polymérase du vih
US20110117193A1 (en) * 2008-01-17 2011-05-19 Duquesne University Of The Holy Spirit Antiretroviral drug formulations for treatment of children exposed to hiv/aids

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004002498A1 (fr) * 2002-06-27 2004-01-08 Glaxo Group Limited Regimes antiviraux

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004002498A1 (fr) * 2002-06-27 2004-01-08 Glaxo Group Limited Regimes antiviraux

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [Online] FRENCH M. ET AL: 'Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study' Database accession no. 12032876 & HIV CLIN. TRIALS vol. 3, no. 3, May 2002 - June 2002, pages 177 - 185 *
DATABASE MEDLINE [Online] PLANA M. ET AL: 'Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine' Database accession no. 15134181 & ANTIVIR THER. vol. 9, no. 2, April 2004, pages 197 - 204 *
DATABASE MEDLINE [Online] PODZAMCZER D. ET AL: 'A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study)' Database accession no. 12212928 & ANTIVIR THER. vol. 7, no. 2, June 2002, pages 81 - 90 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006086865A2 (fr) * 2005-02-21 2006-08-24 Fundacão Oswaldo Cruz-Fiocruz Composition pharmaceutique, processus de preparation de cette composition, utilisation de cette composition dans le traitement de l'immunodeficience causee par une infection par le vih et technique de traitement associee
WO2006086865A3 (fr) * 2005-02-21 2006-12-28 Fundacao Oswaldo Cruz Composition pharmaceutique, processus de preparation de cette composition, utilisation de cette composition dans le traitement de l'immunodeficience causee par une infection par le vih et technique de traitement associee
EP2207553A1 (fr) * 2007-10-02 2010-07-21 Emory University Combinaisons puissantes de zidovudine et médicaments qui réalisent une sélection de la mutation k65r dans la polymérase du vih
CN101878032A (zh) * 2007-10-02 2010-11-03 埃默里大学 齐多夫定和针对hiv聚合酶中k65r突变选择的药剂的强力组合
EP2207553A4 (fr) * 2007-10-02 2010-12-29 Univ Emory Combinaisons puissantes de zidovudine et médicaments qui réalisent une sélection de la mutation k65r dans la polymérase du vih
US20110117193A1 (en) * 2008-01-17 2011-05-19 Duquesne University Of The Holy Spirit Antiretroviral drug formulations for treatment of children exposed to hiv/aids

Also Published As

Publication number Publication date
WO2006001029A3 (fr) 2006-05-11

Similar Documents

Publication Publication Date Title
US9962390B2 (en) Mosapride sustained-release formulation providing pharmacological and clinical effects with once-daily administration
JP5231242B2 (ja) ヌクレオチド及びヌクレオシド系逆転写酵素阻害剤（テノホビル及びラミブジン）を剤形の異なる部分に含む医薬組合せ
JP6122098B2 (ja) オルメサルタンメドキソミルとロスバスタチンまたはその塩とを含む医薬組成物
NO337917B1 (no) Kjemisk stabil fast dose kombinasjon omfattende tenofovir-disoproxil-fumarat og emtricitabin, og anvendelse derav til fremstillingen av et medikament for behandling av en HIV-infeksjon.
AU2008314454A1 (en) Bilayer composition for the sustained release of acetaminophen and tramadol
NO341027B1 (no) Tablett med høyt medikamentinnhold og fremgangsmåte for fremstilling derav
TW201206447A (en) Pharmaceutical formulations
WO2008096369A2 (fr) Préparation pharmaceutique utilisable en thérapie anti-vih
EP2435052B1 (fr) Formes pharmaceutiques solides de lamivudine s'administrant par voie orale avec isomalt
WO2013132208A1 (fr) Combinaisons pharmaceutiques antirétrovirales comprenant de la lamivudine, du festinavir et de la névirapine
KR20150002550A (ko) 타다라필 및 탐수로신을 함유하는 약학적 캡슐 복합 제제
AU2015245217A1 (en) Unit dosage form comprising Emtricitabine, Tenofovir, Darunavir and Ritonavir
AU2018347990B2 (en) Bi-layer pharmaceutical tablet formulation
KR20150056461A (ko) 타다라필 및 암로디핀을 포함하는 복합제제
WO2009106954A1 (fr) Formes pharmaceutiques stables de lamivudine et de ténofovir
WO2006134610A1 (fr) Composition pharmaceutique d'efavirenz presentant un profil de dissolution ameliore
US20110104267A1 (en) Pharmaceutical compositions of antiretrovirals
CA2835272A1 (fr) Composition pharmaceutique antiretrovirale
WO2009106960A2 (fr) Compositions stables de lamivudine, de ténofovir et d'éfavirenz
CA2505130C (fr) Compositions pharmaceutiques
WO2006001029A2 (fr) Compositions antiretrovirales
WO2009037449A1 (fr) Compositions pharmaceutiques solides comprenant un ou plusieurs inhibiteurs du virus de l'herpès et un ou plusieurs inhibiteurs de la transcriptase inverse
WO2018028841A1 (fr) Composé pharmaceutique solide d'abacavir, de lamivudine et d'éfavirenz.
EP3496719A1 (fr) Composition antirétrovirale multi-classe
EP3334419A1 (fr) Composition pharmaceutique solide d'abacavir, de lamivudine et d'éfavirenz

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1429/CHENP/2004

Country of ref document: IN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase in:

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase